Neural tube closure defects result from fundamental failures of developmental processes during neurulation. Most common among these disorders are spina bifida, a failure of caudal tube closure, and anencephaly, a failure of rostral neural tube closure. A rare disorder, craniorachischisis, is a closure failure along the entire anterior-posterior axis from the midbrain-hindbrain boundary to the most caudal end of the neural tube. During neurulation in the mouse, the neural plate undergoes several morphological changes: neural folds are created, migrate toward the midline, and eventually fuse. As migratory cells intercalate with each other, the embryo is lengthened, at the expense of width, within the medial-lateral plane in a process called convergent extension. The first neural tube closure event (closure 1) begins at the boundary between the hindbrain and the cervical region and spreads both rostrally and caudally into the hindbrain and developing spinal cord, respectively. Thus, when closure 1 fails, the entire neural tube from the midbrain to the caudal neural tube remains open, resulting in craniorachischisis 7, 8 , Ptk7 (ref. 9) and Scribble 10,11 all cause craniorachischisis in the mouse, indicating that the non-canonical Wnt signalling pathway is critical for developmental events underlying closure 1 initiation during neurulation. Craniorachischisis in these mutants results from deficits in convergent extension during the migratory movements required to initiate closure 1 (refs 12-14).
Neural tube closure defects result from fundamental failures of developmental processes during neurulation. Most common among these disorders are spina bifida, a failure of caudal tube closure, and anencephaly, a failure of rostral neural tube closure. A rare disorder, craniorachischisis, is a closure failure along the entire anterior-posterior axis from the midbrain-hindbrain boundary to the most caudal end of the neural tube. During neurulation in the mouse, the neural plate undergoes several morphological changes: neural folds are created, migrate toward the midline, and eventually fuse. As migratory cells intercalate with each other, the embryo is lengthened, at the expense of width, within the medial-lateral plane in a process called convergent extension. The first neural tube closure event (closure 1) begins at the boundary between the hindbrain and the cervical region and spreads both rostrally and caudally into the hindbrain and developing spinal cord, respectively. Thus, when closure 1 fails, the entire neural tube from the midbrain to the caudal neural tube remains open, resulting in craniorachischisis 1, 2 . Currently, all known mutations that result in craniorachischisis in the mouse have been mapped to the vertebrate orthologues of components of the PCP pathway, first identified for its role in tissue patterning of the fly 1, 2 . Loss-of-function mutations in Vangl2 (refs 3, 4) , Fzd (Fzd3;Fzd6 double mutants) 5 , Celsr1 (ref. 6) , Dvl (Dvl1;Dvl2 double mutants) 7, 8 , Ptk7 (ref. 9 ) and Scribble 10,11 all cause craniorachischisis in the mouse, indicating that the non-canonical Wnt signalling pathway is critical for developmental events underlying closure 1 initiation during neurulation. Craniorachischisis in these mutants results from deficits in convergent extension during the migratory movements required to initiate closure 1 (refs 12-14) .
Using a three-generation forward genetic screen for recessive mutations affecting neural development 15 ( Supplementary Information,  Fig. S1 ), we identified mouse line 811. Mutant 811 mice were easily distinguished from their littermates, as homozygous mutants within this allelic group developed craniorachischisis (Fig. 1a) . This mutant allele was found to segregate in Mendelian ratios with 48% (129/267) of parents carrying the allele and 12% (232/1984; 1/4 affected × 1/2 female embryos were carriers) of embryos showing a fully open neural tube ( Supplementary Information, Fig. S2 ). By embryonic day (E) 18.5, approximately 33% of the isolated mutant embryos were dead or dying but could still be scored and genotyped.
The genetic lesion underlying the craniorachischisis observed in line 811 was mapped to a 1.8 Mb region of chromosome 3 between rs13477397 and rs1347704 that contains 17 open reading frames. We sequenced the exons containing the 5ʹUTR and coding sequence for the 14 loci without existing mouse models ( Fig. 1b ; Supplementary Information, Methods). This sequence analysis revealed a single base pair substitution within all of the sequences analysed. This point mutation was a T>A transversion in exon 9 of Sec24b. Two different transcript variants can be processed from the Sec24b locus of the mouse (transcript IDs: ENSMUST00000001079, 1079, and ENSMUST00000098616, 98616; Fig. 1c , exon 9 highlighted in red). The T>A transversion is 2078T>A in 1079 and 1834T>A in 98616 (Fig. 1d) . The nucleotide substitution results in truncated proteins, Sec24b
Y613 and Sec24b Y578 in 1079 and 98616, respectively (Fig. 1e) . Confirmation that the neural tube closure phenotype associated with line 811 is caused by the mutation in Sec24b (Sec24b
Y613
) has been provided by a second independently identified mouse mutant that harbours a distinct loss-of-function mutation in Sec24b (Sec24b
S135X
) and also exhibits chraniorachischisis (F. Meijlink, Hubrecht Institute, Netherlands, personal communication). Sec24b is one of four mammalian orthologues of yeast Sec24, and the first vertebrate Sec24 to be characterized in vivo.
Sec24b functions as a cargo-binding component of the COPII vesicle coat [16] [17] [18] [19] . COPII vesicles are the primary pathway for the active transport of secretory proteins from the ER to the Golgi. Thus, as an initial step in the forward secretion of nearly all non-ER-resident membrane and luminal proteins, COPII-mediated vesicle transport has a key role in enabling the proper cellular localization of thousands of proteins. Sec23, the GTPaseactivating member of the complex, and Sec24 components form tight heterodimers in the cytosol, and these complexes are then recruited to sites of active COPII budding -termed ER exit sites. When recruited to the ER membrane, Sec24 proteins package cargo into the vesicle at sites of active budding. Based on co-crystal structural studies 20 , it seems that Sec24b Y613 is truncated before the putative Sec23 binding site. Therefore, we predicted that Sec24b
Y613 would lose the ability to associate with its Sec23 binding partners, rendering it functionally inactive. Indeed, we found that in contrast to wild-type Sec24b, mutant Sec24b Y613 failed to co-immunoprecipitate with either Sec23a or Sec23b in heterologous cells and was not concentrated at ER exit sites marked by another COPII component, Sec13 ( Supplementary  Information, Fig. S3 ). Thus, Sec24b Y613 acts as a loss-of-function allele, encoding a protein that is incapable of associating with other components of the COPII complex and that is not recruited to ER exit sites.
Given that other mouse mutants with craniorachischisis have deficits in convergent extension 12, 14, 21 , we analysed the embryonic morphology of Sec24b mutant embryos during neurulation before neural tube closure. To do this, we examined Sec24b Y613/Y613 mutant and control littermate embryos at E8.5 for deficits in the length:width ratio. A decrease in this ratio reflects a developmental failure in the migratory movements required to lengthen the embryo and facilitate midline fusion 14 . At the 6-, 7-, 8-and 10-somite stages, Sec24b Y613/Y613 mutant embryos were shorter and wider than their littermates, confirming a deficit in the morphogenic movements of convergent extension (Fig. 2a) . These findings indicate that the developmental events underlying craniorachischisis in Sec24b Y613 mutants are shared with other mouse mutants in the PCP-signalling pathway.
Convergent extension-deficient craniorachischisis is common in mouse mutants with defects in the PCP-signalling pathway; thus, we sought to determine whether other PCP-dependent phenotypes were also found in Sec24b Y613/Y613 embryos. First, all mutants isolated at E18.5 were scored for omphalocele, a congenital birth defect in which the intestines, liver and occasionally other organs develop outside the abdomen because the tissues of the abdominal wall fail to fuse at the midline. We observed omphalocele in 45% (n = 38) of the late gestation mutant embryos, but in fewer than 1% (n = 166) of littermate control embryos. Second, we examined fusion of the eyelids in all of the E18.5 Sec24b Y613/Y613 embryos. In nearly all of these mutants (99%, n = 38), the upper and lower eyelids failed to fuse. In contrast, eyelid fusion failure was observed in only 2% (n = 166) of littermate control embryos (Fig. 2b) .
Defects in the orientation of sensory hair cells in the cochlea and the vestibular system are also frequently observed in mice lacking core PCP components 22 . Using immunological techniques to label the cilia of hair cells within these tissues, we examined the orientation of hair cells of the cochlea and vestibular system. In the cochlea, Sec24b Y613/Y613 embryos showed defects in the orientation of both the outer and inner hair cells. In addition, the alignment of both the outer and inner hair cells of the cochlea was abnormal, with hair cells periodically falling out of phase from the row (Fig. 2c) . This defect was present across the entire organ of Corti. In the vestibular system, however, no differences in the orientation of hair cells between Sec24b Y613/Y613 mutant and littermate control embryos were observed. In addition, we examined the orientation of hair follicles of the back skin in Sec24b Y613/Y613 embryos and their littermate controls. Hair follicle orientation of the mutants at this stage seemed relatively normal (data not shown). Therefore, in addition to craniorachischisis, Sec24b Y613/ Y613 mutant mice share most of the phenotypic characteristics of mice harbouring mutations within components of the core PCP-signalling complex, indicating that Sec24b might function by interacting with a component of the PCP pathway.
The role of Sec24b in the formation of COPII vesicles destined to transit between the ER and the Golgi, and the PCP-signalling-dependent phenotypes found in Sec24b Y613/Y613 mutant embryos indicate that Sec24b Many transmembrane proteins are probably sorted into COPII vesicles through cargo-binding sites common to all Sec24 proteins 19 . However, the conservation of four distinct vertebrate paralogues suggests that each Sec24 may have evolved the ability to transport specific and essential cargos. To establish a direct measure of ER export of Vangl2 and to assess the role of Sec24b in the trafficking of Vangl2, we used an in vitro vesicle budding reaction 25 . Using this assay, Vangl2-containing vesicles were formed in a COPII-dependent manner. More importantly, reactions supplemented with recombinant Sec24b, but not with the other Sec24 paralogues, showed a substantial increase in the amount of Vangl2 packaged into COPII vesicles. In contrast, another known COPII cargo protein amyloid precursor protein (APP), which is packaged and transported in a COPII-dependent manner, showed no specificity for any of the Sec24 paralogues (Fig. 4a) . Thus, Vangl2 is preferentially sorted by Sec24b during COPII vesicle formation from the ER.
Two semi-dominant, loss-of-function alleles of Vangl2 have been mapped and isolated using classical genetics: Vangl2 LP (S464N) 10 and Vangl2 Lp-m1Jus (D255E) 3 . Heterozygotes of both alleles exhibit a looped-tail phenotype whereas homozygous mutants exhibit craniorachischisis. Both point mutations map to the cytosolic carboxyterminal domain of Vangl2 and could inhibit the ability of Vangl2 to interact with COPII or other cytosolic chaperones. Therefore, we assessed the ability of Vangl2 looptail mutant proteins to be packaged into COPII vesicles using the in vitro vesicle budding assay. As before, Vangl2 was packaged into vesicles in a COPII-dependent manner but, strikingly, neither Vangl2 S464N nor Vangl2 D255E was capable of entering COPII vesicles (Fig. 4b) . This effect was especially surprising given the conservative D255E substitution found in the Vangl2
Lp-m1Jus allele. Neither mutation depressed COPII budding, as other cargo proteins were still packaged normally ( Supplementary Information, Fig. S4 ). Correspondingly, Vangl2 S464N and Vangl2 D255E colocalized with protein disulphide isomerase (PDI), an ER marker, and failed to reach the plasma membrane (Fig. 4c) .
Our LP mutant mice. As a control, the subcellular localization of β-catenin, a membrane-bound protein not associated with the PCP pathway, was assessed in the same tissue. Vangl2 protein was mislocalized to puncta within the cytoplasm of Sec24b Y613/Y613 mutant embryos, while Vangl2 colocalized with β-catenin at the plasma membrane in wild-type embryos (Fig. 5) . As reported previously 26 , Vangl2 trafficking to the plasma membrane in Vangl2 LP mutants was aberrant (Fig. 5) . In contrast, the pattern of subcellular distribution of Fzd3 in cells of the neural tube was comparable in wildtype, Sec24b Y613/Y613 and Vangl2 LP mice ( Supplementary Information, Fig. S5 that most human genetic diseases are not recessive but rather arise from the interactions of multiple loci, human mutations in Sec24b are likely to contribute to spina bifida. Our analysis of Sec24b Y613 identifies a new mechanism of protein regulation during development. Sec24b is one of four paralogues that function in the trafficking of secretory proteins between the ER and Golgi. Thus, loss of Sec24b function would be predicted to lead to deficits in the cell surface expression of some transmembrane proteins. Sec24b mutant embryos, though clearly developmentally abnormal for neural tube closure, are relatively normal with respect to many other developmental processes. Vangl2 may be one of a small set of COPII cargo proteins whose transport is strictly dependent on Sec24b. Nonetheless, our findings indicate that cargo specificity has evolved between the four Sec24 paralogues, with Sec24b being specifically required for trafficking of a core PCP component, Vangl2, and the establishment of planar cell polarity, convergent extension and neural tube closure.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/.
Note: Supplementary Information is available on the Nature Cell Biology website.
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M E T H O D S
METHODS
Mutagenesis. C57BL/6 (BL6) mice were injected with ENU as described previously [27] [28] [29] . Briefly, BL6 male mice were injected with 3 × 100 mg kg -1 body weight of ENU to induce random mutations throughout the genome. Using a threegeneration forward genetic screen, we outbred and isolated the mutations in C3H/ He mice to facilitate mapping by polymorphism. Resulting G1 fathers were mated to their G2 daughters and embryos were screened for developmental anomalies ( Supplementary Information, Fig. S1 ).
Mapping. The genetic lesion responsible for craniorachischisis in line 811 was mapped via backcross ( Supplementary Information, Fig. S3 ) using standard linkage analysis with a panel of PCR polymorphisms between C57BL/6 (BL6) and C3H/He (C3H) mice ( Supplementary Information, Table S1 ) to the distal end of chromosome 3. Analyses at several other polymorphisms placed 811 within a 3.7 Mb region between D3MIT319 and D3MIT254. We analysed the D3MIT319 recombinants (10/527) at rs13477397, rs4231957 and rs13477402 and found recombination at rs13477397 (9/531) but not at rs4231957 or rs13477402. Similarly, we analysed the recombinants at D3MIT254 (3/509), rs13477404 and rs13477406 as well as rs4231957 and rs13477402 and identified a single recombination event that spanned D3MIT254 through rs13477404. Thus, 811 was determined to be in the 1.8 Mb region between rs13477397 and rs1347704 containing 17 open reading frames. Of these 17 predicted genes, 3 had mouse models that did not exhibit craniorachischisis and could be eliminated. We sequenced the exons containing the 5ʹUTR and the coding sequence for all of the 14 remaining loci (ENSMUSG00000074236, Elov6, ENSMUSG00000080139, ENSMUSG00000068627, Rrh, Nola1, Cfi, Pla2g12a, 9030408N13Rik (Ccdc109b), Sec24b, Rpl12, Col25a1, ENSMUSG00000065788) using DNA isolated from two mutants and one BL6 control mouse. Several of these genes were sequenced by the Harvard University Partners Genomics Facility.
Genotyping. Sec24b
Y613 creates a restriction enzyme-sensitive polymorphism. This line is genotyped by amplification of an approximately 200 bp fragment with 5ʹ-TCAAACACCATCGTGAGGTGCC-3ʹ and 5ʹ-ACCCGAAACTCACCATCAATAACT-3ʹ, followed by subsequent digestion with MseI.
Convergent extension.
Mutants and controls from E8.5 litters were isolated and then binned based on somite number. The length and width of each embryo was then quantified, the length:width ratio calculated, the embryos genotyped and the length:width ratio compared between mutants and controls by ANOVA followed by Student Newman-Keuls post hoc. n = 7, 8, 7 and 9 mutants at the 6-, 7-, 8-and 10-somite stages, respectively.
Immunohistochemisty. E18.5 mouse cochlea staining was performed as described previously 5 . Staining of E10.5 spinal cords was performed as described with minor modifications 26 . Embryos were fixed in 2% paraformaldehyde, washed twice in PBS, embedded in OCT and frozen. 10-μm sections were collected on slides and antigen retrieval was performed by incubating the slides in sodium citrate buffer (10 mM Sodium Citrate and 0.05% Tween-20, at pH 6.0) for 30 min at 95 °C. Slides were washed three times in PBS and incubated overnight at 4 °C with PBS containing anti-Vangl2 (1:150), anti-β-catenin (1:250) and/or anti-Fzd-3 (1:50), 10% normal goat serum and 0.4% Triton X-100. The following day, slides were washed and incubated with the appropriate fluorescent secondary antibodies (1:400) for 4 h at room temperature.
In Vitro COPII vesicle budding assay. Procedure for making cell-free mRNA, semi-intact cells and subsequent in vitro translation was preformed as described previously 25, 30 , with some modifications. The vesicle formation reaction and vesicle purification procedure was essentially as described previously 31 , with some modifications. In detail, COS7 cells grown in 3 × 100 mm plates were washed in PBS, removed from plates with trypsin, and washed again in PBS containing 10 μg ml -1 soybean trypsin inhibitor. Then, cells were permeablized with 40 μg ml -1 digitonin for 5 min in ice-cold KHM buffer (110 mM KOAc, 20 mM Hepes at pH 7.2 and 2 mM Mg(OAC) 2 ) and washed and resuspended in 100 μl KHM. Endogenous RNA was degraded after addition of 1 mM CaCl 2 and 10 μg ml -1 micrococcal nuclease and incubated at room temperature for 12 min. After incubation, the nuclease reaction was stopped by addition of 4 mM EGTA, and cells were pelleted and washed. Semi-intact RNA-free cells were resuspended in KHM buffer such that the measurement of absorbance (600 nm) for 5 μl of cells in 500 μl KHM was 0.08. These cells were added to an in vitro translation reaction with rabbit reticulocyte lysate (Promega, Flexi) and RNA encoding HA-Vangl2, which was incubated for 60 min at 30 °C. Then, these donor membranes were washed to remove non-translocated protein products and resuspended in KHM.
To form vesicles, donor membranes with newly synthesized HA-Vangl2 were combined where indicated with rat liver cytosol, ATP regenerating system (40 mM creatine phosphate, 0.2 mg ml -1 creatine phosphokinase and 1 mM ATP), 0.2 mM GTP and/or recombinant COPII proteins, followed by incubation at 30 °C for 1 h. Newly formed vesicles were separated from the more rapidly sedimenting donor membranes by centrifugation at 13,000g for 12 min. Vesicles were collected by centrifugation at 115000g for 25 min. Vesicle pellets were resuspended and washed in 100 μl cold KHM, centrifuged again and finally solubilized in 16 μl of buffer C (10 mM Tris-HCl at pH 7.6, 100 mM NaCl, 1% Triton X-100 plus protease inhibitor mixture) and Laemmli sample buffer. Vesicle fractions and original donor membranes were resolved on SDS-PAGE, transferred onto PVDF membranes and subjected to immunoblotting to detect HA-Vangl2 and the positive control endogenous cargo proteins, amyloid precursor protein, ERGIC-53 and Sec22.
Antibodies. Anti-Sec13 antiserum was raised in rabbits injected with a purified recombinant His-tagged human full-length Sec13 produced in baculovirusinfected SF9 cells. Anti-Sec22 antiserum was raised in rabbits injected with the peptide (CG)-HSEFDEQHGKKVPTVSRPYSFIEFDT (residues 91-116) conjugated to rabbit serum albumin. Anti-HA was from Covance (16B12). Anti-Myc was from Cell Signaling Technologies (2276). Anti-Flag and anti-amyloid precursor protein were from Sigma (F3165 and A8717, respectively). Monoclonal anti-protein disulphide isomerase was a gift from S. Fuller (European Molecular Biology Laboratory-Heidelberg, Germany). Anti-ERGIC-53/LMAN-1/p58 antiserum was generated as described previously 32 . Anti-Vangl2 was a gift from P. Gros (McGill University, Quebec, Canada) and anti-Fzd-3 was a gift from J. Nathans (Johns Hopkins University, MD, USA). Anti-β-catenin was from Cell Signaling Technologies (2677). Anti-mouse and anti-rabbit HRP conjugates were from GE Healthcare UK (NXA931 and NA934V, respectively). Anti-mouse FITC conjugate and anti-rabbit TRITC conjugate were both from Jackson ImmunoResearch (715-095-151 and 711-025-152, respectively).
Immunofluorescence. COS7 cells grown on coverslips were transiently transfected with plasmids encoding 3×HA-Vangl2 wild-type, Lp255, or Lp464 or 6×Myc-Sec24b wild-type or Y613 using Lipofectamine 2000 according to the manufacturer's recommended protocol. Twenty hours later, cells were processed by immunofluorescence. All subsequent steps were at room temperature and all washing steps used three changes of 2 ml PBS. Cells on coverslips were fixed in 2.5% paraformaldehyde for 15 min and washed. Next, they were permeablized in 0.1% Trition X-100 in PBS for 1 min and washed. Cells were then blocked with 1% BSA in PBS for 30 min. Next, cells on coverslips were incubated with the indicated primary antibodies diluted in 1% BSA for 1 h and washed. Then, they were incubated in secondary anti-rabbit or anti-mouse fluorescent conjugates diluted in 1% BSA for 1 h and washed. Finally, coverslips were briefly incubated in 1 µg ml -1 DAPI and were mounted on glass slides in mowiol mounting medium. Cells were imaged using a Zeiss AxioObserver Z1 fluorescent microscope and images were captured and merged using Metamorph software from Molecular Devices.
Immunoprecipatations. COS7 cells grown in wells of a 6-well plate were transiently transfected with 6×Myc-Sec24b wild-type or Y613, and with Flag-Sec23a or Flag-Sec23b, using Lipofectamine 2000 according to the manufacturer's recommended protocol. Twenty-four hours later, cells were washed twice in PBS. Then, cells were solubilized in 200 μl of RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M Na 2 PO 4 and protease inhibitor mixture at pH 7.2). Cell lysates were cleared by centrifugation at 15,000g for 10 min and the supernatant was transferred to a new tube. A 20 μl sample of input lysate was reserved in a separate tube and mixed with buffer C and Laemmli sample buffer. A primary anti-Myc antibody was added to a concentration of 1:300 and rotated at 4 °C for 3 h. Then, 40 μl of 50% slurry washed Protein A-sepharose beads was added and the lysate was again rotated at 4 °C for 2 h. Beads were pelleted at 2,000g and washed four times in RIPA buffer. The beads were resus-DOI: 10.1038/ncb2002 pended in 80 μl of Buffer C and 2× Laemmli sample buffer. Finally, samples were resolved on SDS-PAGE, transferred onto PVDF membranes and subjected to immunoblotting to detect Myc-Sec24b and Flag-Sec23.
Recombinant protein purification. Recombinant human Sar1 H79G was overexpressed in E. Coli and purified as described previously 31 . Human Flag-Sec23a/ His-Sec24a, Flag-Sec23a/His-Sec24b, Flag-Sec23a/His-Sec24c and Flag-Sec23a/ His-Sec24d were expressed in SF9 cells using a baculovirus system and purified as described previously 31 .
Materials. Rabbit muscle creatine phosphokinase, creatine phosphate, ATP, GTP and protease inhibitor mixture tablets were from Roche Applied Science. Protein A-sepharose was from BioVision. Rat liver cytosol was prepared as described previously 31 . Trypsin 0.05% with EDTA was from Invitrogen. Soybean trypsin inhibitor was from Fluka Biochemika. Micrococcal nuclease from Staphylococcus aureus was from USB-Affymetrix, dissolved in 50 mM glycine, 5 mM CaCl 2 at pH 9.2 and stored in 1 mg ml -1 aliquots. Digitonin was from Sigma and dissolved in DMSO at 40 mg ml -1 .
Plasmids. 3×HA-Vangl2 Lp255 and Lp464 were created using site-directed mutagenesis on the pCS2 3×HA-Vangl2 wild-type plasmid according to the QuikChange protocol from Stratagene, using the respective primers: 5ʹ-GTCG
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Figure S1 Schematic diagram of the recessive screen for novel alleles affecting neural development. C57BL/6 male mice (8-10 weeks old) were injected with 3X100mg/kg body weight N-ethylnitrosourea (ENU). F1 males that regained fertility were mated to C3H/He females to produce G1 male mice (lines). Each of these G1 males was in turn mated to C3H/He females to produce G2 daughters, some of which are presumed heterozygous for a given mutation. After crossing the G2 females to their G1 fathers, recessive mutations were produced and scored for developmental anomalies. 
